Stromal expression of ASPN in the TME of HER2- and HER3-expressing metastatic prostate cancer supports a role for this pathway in metastatic disease and highlights a potential therapeutic vulnerability, especially due to the development of ADCs designed to target HER2 and HER3. Here, ERBB2 is linked to metastatic neoplasm.